Xenon Pharmaceuticals’ (XENE) “Outperform” Rating Reaffirmed at William Blair

William Blair reiterated their outperform rating on shares of Xenon Pharmaceuticals (NASDAQ:XENE) in a report released on Friday,RTT News reports. William Blair also issued estimates for Xenon Pharmaceuticals’ Q1 2026 earnings at $0.00 EPS, Q2 2026 earnings at ($1.01) EPS, Q3 2026 earnings at ($1.03) EPS and Q4 2026 earnings at ($1.06) EPS.

Several other equities analysts also recently commented on the company. HC Wainwright reiterated a “buy” rating and issued a $53.00 target price on shares of Xenon Pharmaceuticals in a research report on Monday, February 24th. Deutsche Bank Aktiengesellschaft started coverage on Xenon Pharmaceuticals in a research report on Tuesday, February 11th. They set a “buy” rating and a $67.00 price objective for the company. Finally, Needham & Company LLC restated a “buy” rating and set a $60.00 price objective on shares of Xenon Pharmaceuticals in a research report on Wednesday, November 13th. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $57.38.

Xenon Pharmaceuticals Trading Down 3.4 %

Xenon Pharmaceuticals stock opened at $37.02 on Friday. The company has a market capitalization of $2.82 billion, a PE ratio of -13.13 and a beta of 1.20. Xenon Pharmaceuticals has a 12 month low of $33.27 and a 12 month high of $50.99. The stock has a 50-day moving average price of $39.27 and a two-hundred day moving average price of $40.30.

Xenon Pharmaceuticals (NASDAQ:XENE) last posted its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.84) EPS for the quarter, beating the consensus estimate of ($0.89) by $0.05. As a group, analysts predict that Xenon Pharmaceuticals will post -3.1 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CFO Sherry Aulin sold 18,709 shares of the firm’s stock in a transaction that occurred on Wednesday, December 18th. The stock was sold at an average price of $41.21, for a total transaction of $770,997.89. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Ian Mortimer sold 22,468 shares of the firm’s stock in a transaction that occurred on Friday, January 24th. The stock was sold at an average price of $40.20, for a total value of $903,213.60. Following the sale, the chief executive officer now directly owns 31,302 shares of the company’s stock, valued at $1,258,340.40. This represents a 41.79 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 57,492 shares of company stock valued at $2,334,969 over the last 90 days. Company insiders own 5.52% of the company’s stock.

Institutional Investors Weigh In On Xenon Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in XENE. Blue Trust Inc. grew its stake in Xenon Pharmaceuticals by 174.7% in the third quarter. Blue Trust Inc. now owns 1,008 shares of the biopharmaceutical company’s stock valued at $39,000 after acquiring an additional 641 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its stake in Xenon Pharmaceuticals by 21.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,740 shares of the biopharmaceutical company’s stock valued at $106,000 after acquiring an additional 487 shares during the period. abrdn plc grew its stake in Xenon Pharmaceuticals by 16.9% in the third quarter. abrdn plc now owns 248,311 shares of the biopharmaceutical company’s stock valued at $9,776,000 after acquiring an additional 35,809 shares during the period. Harbor Capital Advisors Inc. grew its stake in Xenon Pharmaceuticals by 99.3% in the third quarter. Harbor Capital Advisors Inc. now owns 48,063 shares of the biopharmaceutical company’s stock valued at $1,892,000 after acquiring an additional 23,947 shares during the period. Finally, Assetmark Inc. grew its stake in Xenon Pharmaceuticals by 7.9% in the third quarter. Assetmark Inc. now owns 19,670 shares of the biopharmaceutical company’s stock valued at $774,000 after acquiring an additional 1,435 shares during the period. Institutional investors and hedge funds own 95.45% of the company’s stock.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.